The fraud investigations of Bristol-Myers Squibb and the University of Medicine and Dentistry of New Jersey posed a dilemma for U.S. Attorney Christopher Christie: how to enforce the law without putting them out of business. Christie chose deferred prosecution, which is relatively new terrain in white-collar cases. Perhaps that's one reason why his deferred prosecutions came under fire at an ABA symposium for what was called excessive prosecutorial involvement in business operations.
Deferred White-Collar Prosecutions: New Terrain, Few Signposts
New Jersey Law Journal
April 11, 2006
This article requires premium access
This article requires premium access to Law.com. Please sign in or subscribe to read the full text.